Regeneron CEO: Anticipating PCSK9 launch, but worried about pricing debate

Regeneron ($REGN) is charging toward an FDA submission for its cholesterol-fighting drug candidate alirocumab. And in hopes of approval, it's working on launch plans with partner Sanofi ($SNY). But in the meantime, CEO Leonard Schleifer says he's worried that the brouhaha over drug prices might undermine Regeneron's pricing power. Report